These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 26455499)

  • 1. Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.
    Edeline J; Crouzet L; Campillo-Gimenez B; Rolland Y; Pracht M; Guillygomarc'h A; Boudjema K; Lenoir L; Adhoute X; Rohou T; Boucher E; Clément B; Blanc JF; Garin E
    Eur J Nucl Med Mol Imaging; 2016 Apr; 43(4):635-43. PubMed ID: 26455499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
    Vilgrain V; Pereira H; Assenat E; Guiu B; Ilonca AD; Pageaux GP; Sibert A; Bouattour M; Lebtahi R; Allaham W; Barraud H; Laurent V; Mathias E; Bronowicki JP; Tasu JP; Perdrisot R; Silvain C; Gerolami R; Mundler O; Seitz JF; Vidal V; Aubé C; Oberti F; Couturier O; Brenot-Rossi I; Raoul JL; Sarran A; Costentin C; Itti E; Luciani A; Adam R; Lewin M; Samuel D; Ronot M; Dinut A; Castera L; Chatellier G;
    Lancet Oncol; 2017 Dec; 18(12):1624-1636. PubMed ID: 29107679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis.
    Cho YY; Lee M; Kim HC; Chung JW; Kim YH; Gwak GY; Bae SH; Kim do Y; Heo J; Kim YJ
    PLoS One; 2016; 11(5):e0154986. PubMed ID: 27149067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib.
    de la Torre MA; Buades-Mateu J; de la Rosa PA; Lué A; Bustamante FJ; Serrano MT; Testillano M; Lorente S; Arenas JI; Gil C; Iñarrairaegui M; Sangro B
    Liver Int; 2016 Aug; 36(8):1206-12. PubMed ID: 26910784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.
    Ricke J; Bulla K; Kolligs F; Peck-Radosavljevic M; Reimer P; Sangro B; Schott E; Schütte K; Verslype C; Walecki J; Malfertheiner P;
    Liver Int; 2015 Feb; 35(2):620-6. PubMed ID: 24930619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
    Pan T; Li XS; Xie QK; Wang JP; Li W; Wu PH; Zhao M
    Clin Radiol; 2014 Dec; 69(12):e553-61. PubMed ID: 25304928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.
    Ye HH; Ye JZ; Xie ZB; Peng YC; Chen J; Ma L; Bai T; Chen JZ; Lu Z; Qin HG; Xiang BD; Li LQ
    World J Gastroenterol; 2016 Apr; 22(13):3632-43. PubMed ID: 27053855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of positron emission tomography and bremsstrahlung imaging to detect particle distribution in patients undergoing yttrium-90 radioembolization for large hepatocellular carcinomas or associated portal vein thrombosis.
    Padia SA; Alessio A; Kwan SW; Lewis DH; Vaidya S; Minoshima S
    J Vasc Interv Radiol; 2013 Aug; 24(8):1147-53. PubMed ID: 23792126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
    Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of hepatocellular carcinoma with portal vein thrombosis.
    Quirk M; Kim YH; Saab S; Lee EW
    World J Gastroenterol; 2015 Mar; 21(12):3462-71. PubMed ID: 25834310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
    Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
    Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization.
    Lorenzin D; Pravisani R; Leo CA; Bugiantella W; Soardo G; Carnelutti A; Umberto B; Risaliti A
    Cancer Biother Radiopharm; 2016 Mar; 31(2):65-9. PubMed ID: 26986817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
    Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
    Trials; 2014 Dec; 15():474. PubMed ID: 25472660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Radioembolization in the Treatment of Hepatocellular Carcinoma with Portal Vein Invasion: Resin versus Glass Microspheres.
    Biederman DM; Titano JJ; Tabori NE; Pierobon ES; Alshebeeb K; Schwartz M; Facciuto ME; Gunasekaran G; Florman S; Fischman AM; Patel RS; Nowakowski FS; Kim E
    J Vasc Interv Radiol; 2016 Jun; 27(6):812-821.e2. PubMed ID: 27062356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
    Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
    Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis.
    Jeong SW; Jang JY; Shim KY; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim KH; Kim JH
    Gut Liver; 2013 Nov; 7(6):696-703. PubMed ID: 24312711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Song DS; Song MJ; Bae SH; Chung WJ; Jang JY; Kim YS; Lee SH; Park JY; Yim HJ; Cho SB; Park SY; Yang JM
    J Gastroenterol; 2015 Apr; 50(4):445-54. PubMed ID: 25027973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma.
    Cho JY; Paik YH; Park HC; Yu JI; Sohn W; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    Liver Int; 2014 May; 34(5):795-801. PubMed ID: 24350564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.
    Ricke J; Klümpen HJ; Amthauer H; Bargellini I; Bartenstein P; de Toni EN; Gasbarrini A; Pech M; Peck-Radosavljevic M; Popovič P; Rosmorduc O; Schott E; Seidensticker M; Verslype C; Sangro B; Malfertheiner P
    J Hepatol; 2019 Dec; 71(6):1164-1174. PubMed ID: 31421157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
    Kodama K; Kawaoka T; Aikata H; Uchikawa S; Nishida Y; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Kimura T; Nagata Y; Chayama K
    Oncology; 2018; 94(4):215-222. PubMed ID: 29428943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.